FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896863217> ?p ?o ?g. }

• W2896863217 endingPage "4" @default.
• W2896863217 startingPage "1" @default.
• W2896863217 abstract "The programmed cell death protein-1 (PD-1) inhibitor nivolumab has been recently approved as an effective and safe treatment for patients with refractory/relapsed Hodgkin’s lymphomas. Dermatological adverse events, mainly skin rash, have been reported in 1–5% of patients. We describe a case of de novo psoriasis vulgaris (PsV), diagnosed after nivolumab treatment for refractory Hodgkin’s lymphoma. After administration of 6 cycles, skin lesions appeared in the right tibia, forearms, and dorsum of hands, and biopsy confirmed the diagnosis of PsV. The lesions completely resolved after autologous stem cell transplantation (ASCT) which was performed in the context of the treatment for the primary disease. PsV is an inflammatory skin disease, and it is considered to be mediated through cytotoxic T-cells. PD-1 blockage may lead to expansion of such T-cells, resulting thus in PsV appearance. The early published studies showed that nivolumab represents a safe treatment approach. PsV occurrence has not been reported so far in patients treated with nivolumab for hematological diseases, and it seems that long-term follow-up is necessary to fully clarify the entirety of PD-1 inhibitors’ skin adverse events. Additionally, this clinical observation provides an evidence for a potential exploitation of ASCT in refractory and severe forms of PsV." @default.
• W2896863217 created "2018-10-26" @default.
• W2896863217 creator A5008136287 @default.
• W2896863217 creator A5016108398 @default.
• W2896863217 creator A5049251123 @default.
• W2896863217 creator A5057769687 @default.
• W2896863217 creator A5073231847 @default.
• W2896863217 creator A5088887795 @default.
• W2896863217 creator A5090726389 @default.
• W2896863217 date "2018-10-16" @default.
• W2896863217 modified "2023-09-27" @default.
• W2896863217 title "De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin’s Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation" @default.
• W2896863217 cites W1923122596 @default.
• W2896863217 cites W1998207985 @default.
• W2896863217 cites W2050201865 @default.
• W2896863217 cites W2052382030 @default.
• W2896863217 cites W2068089617 @default.
• W2896863217 cites W2085795043 @default.
• W2896863217 cites W2098205979 @default.
• W2896863217 cites W2324653442 @default.
• W2896863217 cites W2343144688 @default.
• W2896863217 cites W2370678872 @default.
• W2896863217 cites W2412725897 @default.
• W2896863217 cites W2504623699 @default.
• W2896863217 cites W2531852397 @default.
• W2896863217 cites W2544356993 @default.
• W2896863217 cites W2586675028 @default.
• W2896863217 cites W2610082331 @default.
• W2896863217 cites W2734832706 @default.
• W2896863217 cites W2776516714 @default.
• W2896863217 cites W2794872274 @default.
• W2896863217 cites W2800377815 @default.
• W2896863217 cites W2802457711 @default.
• W2896863217 cites W2807540173 @default.
• W2896863217 cites W3061157080 @default.
• W2896863217 cites W4230648998 @default.
• W2896863217 doi "https://doi.org/10.1155/2018/6215958" @default.
• W2896863217 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6206568" @default.
• W2896863217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410803" @default.
• W2896863217 hasPublicationYear "2018" @default.
• W2896863217 type Work @default.
• W2896863217 sameAs 2896863217 @default.
• W2896863217 citedByCount "3" @default.
• W2896863217 countsByYear W28968632172022 @default.
• W2896863217 countsByYear W28968632172023 @default.
• W2896863217 crossrefType "journal-article" @default.
• W2896863217 hasAuthorship W2896863217A5008136287 @default.
• W2896863217 hasAuthorship W2896863217A5016108398 @default.
• W2896863217 hasAuthorship W2896863217A5049251123 @default.
• W2896863217 hasAuthorship W2896863217A5057769687 @default.
• W2896863217 hasAuthorship W2896863217A5073231847 @default.
• W2896863217 hasAuthorship W2896863217A5088887795 @default.
• W2896863217 hasAuthorship W2896863217A5090726389 @default.
• W2896863217 hasBestOaLocation W28968632171 @default.
• W2896863217 hasConcept C121332964 @default.
• W2896863217 hasConcept C121608353 @default.
• W2896863217 hasConcept C126322002 @default.
• W2896863217 hasConcept C141071460 @default.
• W2896863217 hasConcept C142424586 @default.
• W2896863217 hasConcept C151730666 @default.
• W2896863217 hasConcept C16005928 @default.
• W2896863217 hasConcept C197934379 @default.
• W2896863217 hasConcept C2775934546 @default.
• W2896863217 hasConcept C2777408962 @default.
• W2896863217 hasConcept C2777701055 @default.
• W2896863217 hasConcept C2778570526 @default.
• W2896863217 hasConcept C2779050716 @default.
• W2896863217 hasConcept C2779338263 @default.
• W2896863217 hasConcept C2779343474 @default.
• W2896863217 hasConcept C2780030458 @default.
• W2896863217 hasConcept C2780439664 @default.
• W2896863217 hasConcept C2780564577 @default.
• W2896863217 hasConcept C2911091166 @default.
• W2896863217 hasConcept C71924100 @default.
• W2896863217 hasConcept C86803240 @default.
• W2896863217 hasConcept C87355193 @default.
• W2896863217 hasConceptScore W2896863217C121332964 @default.
• W2896863217 hasConceptScore W2896863217C121608353 @default.
• W2896863217 hasConceptScore W2896863217C126322002 @default.
• W2896863217 hasConceptScore W2896863217C141071460 @default.
• W2896863217 hasConceptScore W2896863217C142424586 @default.
• W2896863217 hasConceptScore W2896863217C151730666 @default.
• W2896863217 hasConceptScore W2896863217C16005928 @default.
• W2896863217 hasConceptScore W2896863217C197934379 @default.
• W2896863217 hasConceptScore W2896863217C2775934546 @default.
• W2896863217 hasConceptScore W2896863217C2777408962 @default.
• W2896863217 hasConceptScore W2896863217C2777701055 @default.
• W2896863217 hasConceptScore W2896863217C2778570526 @default.
• W2896863217 hasConceptScore W2896863217C2779050716 @default.
• W2896863217 hasConceptScore W2896863217C2779338263 @default.
• W2896863217 hasConceptScore W2896863217C2779343474 @default.
• W2896863217 hasConceptScore W2896863217C2780030458 @default.
• W2896863217 hasConceptScore W2896863217C2780439664 @default.
• W2896863217 hasConceptScore W2896863217C2780564577 @default.
• W2896863217 hasConceptScore W2896863217C2911091166 @default.
• W2896863217 hasConceptScore W2896863217C71924100 @default.
• W2896863217 hasConceptScore W2896863217C86803240 @default.
• W2896863217 hasConceptScore W2896863217C87355193 @default.

• next